XNAS · Healthcare · Biotechnology
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | -0.42 | -0.50 | -19.05% | $8.9M | ❌ Miss | -0.52% | -6.06% | — |
| 2026-03-05 | Q4 2025 | -0.48 | -0.34 | +29.17% | $23.0M | ✅ Beat | -2.65% | -7.29% | +1.97% |
| 2025-11-17 |
| Q3 2025 |
| -0.50 |
| -0.49 |
| +2.00% |
| $6.1M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-13 | Q2 2025 | -0.38 | -0.66 | -73.68% | $5.5M | ❌ Miss | -6.23% | -8.20% | -4.59% |
| 2025-03-27 | Q4 2024 | — | 0.48 | — | $60.0M | — | -1.70% | -18.47% | +1.27% |
| 2024-11-18 | Q3 2024 | -0.29 | -0.12 | +58.62% | $55.6M | ✅ Beat | -0.13% | -2.94% | -13.94% |
| 2024-08-13 | Q2 2024 | -0.31 | -0.18 | +41.94% | $20.2M | ✅ Beat | +1.74% | +2.09% | +8.25% |
| 2024-05-14 | Q1 2024 | -0.22 | -0.04 | +80.45% | $32.9M | ✅ Beat | -4.48% | -8.36% | +11.64% |
Showing last 8 quarters.